Sort   by:  
 Page size 
UnknownPET ligands [<sup>18</sup>F]LSN3316612 and [<sup>11</sup>C]LSN3316612 quantify <i>O</i>-linked-β-<i>N</i>-acetyl-glucosamine hydrolase in the brain.
Not available
S-EPMC8494060 | biostudies-literature
UnknownImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536 | biostudies-literature
UnknownEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591 | biostudies-literature
UnknownAntidepressant use in low- middle- and high-income countries: a World Mental Health Surveys report.
Not available
S-EPMC10071359 | biostudies-literature
UnknownTrial of Solanezumab in Preclinical Alzheimer's Disease.
Not available
S-EPMC10559996 | biostudies-literature
UnknownFrailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031 | biostudies-literature
UnknownDonanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Not available
S-EPMC10352931 | biostudies-literature
UnknownLong-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7616743 | biostudies-literature
UnknownEffects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867 | biostudies-literature
UnknownBaricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Not available
S-EPMC7745180 | biostudies-literature
Sort   by:  
 Page size